Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 255 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asymptomatic Condition Clear all
Terminated Phase 2 Interventional Results available

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

NCT02432690
View directory record Official record
Conditions
Cancer, Ovarian Cancer
Interventions
BBI503
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

NCT00000750
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 9 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Efficacy Study of ABR-215050 to Treat Prostate Cancer

NCT00560482
View directory record Official record
Conditions
Prostate Cancer
Interventions
ABR-215050, tasquinimod, Placebo
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
54
States / cities
Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

NCT00514917
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Leuprolide, Bicalutamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 4 Interventional

Nasal Antisepsis for C. Auris Prevention

NCT06282510
View directory record Official record
Conditions
Candida Auris Infection, Colonization, Asymptomatic
Interventions
Povidone Iodine Topical
Drug
Lead sponsor
Mary K Hayden
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Hinsdale, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Early Phase 1 Interventional

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01747798
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
auranofin, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting No phase listed Observational

Long-Term Outcomes of Children With Congenital CMV in New York State

NCT06226558
View directory record Official record
Conditions
Congenital CMV Infection, Sensorineural Hearing Loss
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
0 Days to 1 Year
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

NCT00000633
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
2
States / cities
Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

NCT00001036
View directory record Official record
Conditions
HIV Infections
Interventions
Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 30, 2026, 1:36 PM EDT
Withdrawn No phase listed Observational

Cardiac 3D MRI in Pediatric Cancer Patients

NCT02130934
View directory record Official record
Conditions
Childhood Cancer
Interventions
Cardiac 3D MRI
Procedure
Lead sponsor
Majd Makhoul
Other
Eligibility
8 Years to 26 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

ShuntCheck Performance Characteristics in Asymptomatic Pseudotumor Cerebri Patients

NCT04309383
View directory record Official record
Conditions
Pseudotumor Cerebri
Interventions
ShuntCheck
Diagnostic Test
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

Making Sense of a Positive Genetic Test Result for Huntington Disease

NCT00539747
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Baltimore, Maryland • Bethesda, Maryland • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 1:36 PM EDT
Not listed No phase listed Observational

Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants

NCT01349738
View directory record Official record
Conditions
Bacteriuria, Urinary Tract Infections, Asymptomatic Infections, Transplantation Infection
Interventions
Antibiotic
Drug
Lead sponsor
Rice, James C., M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

NCT03072238
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Ipatasertib, Abiraterone, Placebo, Prednisone/Prednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
32
States / cities
Chandler, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

NCT00520481
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
IMC-A12 (Cixutumumab)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial

NCT04289753
View directory record Official record
Conditions
Prostate Specific Antigen Screening, Asymptomatic Bacteriuria, Type 2 Diabetes
Interventions
EHR clinical decision support nudges, Brief clinician education
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
37,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Not applicable Interventional

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

NCT03674307
View directory record Official record
Conditions
Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Interventions
No screening, Regular Screening
Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
3,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351
View directory record Official record
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

NCT07728175
View directory record Official record
Conditions
Genetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive
Interventions
Sirolimus (rapamycin), Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Observation for Patients With Asymptomatic CNS Metastatic Disease

NCT02866981
View directory record Official record
Conditions
Cancer, Metastatic Cancer
Interventions
Observation
Other
Lead sponsor
The Cooper Health System
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Lycopene in Treating Patients With Metastatic Prostate Cancer

NCT00068731
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337
View directory record Official record
Conditions
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Interventions
Clinical Observation, Lenalidomide, Quality-of-Life Assessment
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
601
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 1:36 PM EDT